(NTLA) Intellia Therapeutics - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US45826J1051
Stock: Gene Editing, In Vivo, CAR-T, NK Cell, Autoimmune
Total Rating 31
Risk 36
Buy Signal -0.40
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 97.8% |
| Relative Tail Risk | -7.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.69 |
| Alpha | -4.56 |
| Character TTM | |
|---|---|
| Beta | 1.499 |
| Beta Downside | 1.108 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.36% |
| CAGR/Max DD | -0.38 |
Description: NTLA Intellia Therapeutics January 20, 2026
Intellia Therapeutics (NASDAQ:NTLA) is a Cambridge-based, clinical-stage biotech that develops curative in-vivo genome-editing therapies using its CRISPR-Cas9 platform. Its lead candidates are NTLA-2001 (Phase 1 for transthyretin amyloidosis) and NTLA-2002 (Phase 1/2 for hereditary angioedema). The firm also pursues engineered cell-therapy programs, partnering with AvenCell (allogeneic universal CAR-T), Kyverna (CD19 CAR-T for B-cell autoimmune disease), ONK Therapeutics (engineered NK cells) and ReCode Therapeutics (genomic medicines for cystic fibrosis).
Key recent metrics: as of Q2 2024 Intellia reported $210 million of cash and marketable securities, a cash-burn rate of roughly $120 million per year, and a market capitalization near $7 billion. The broader CRISPR-based therapeutics market is projected to grow at a 15-18% CAGR through 2030, driven by expanding FDA acceptance of gene-editing modalities and increasing payer willingness to fund curative treatments.
For a deeper look at NTLA’s valuation and risk profile, you may find ValueRay’s analyst notes worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -445.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.45 > 0.02 and ΔFCF/TA -13.65 > 1.0 |
| NWC/Revenue: 848.7% < 20% (prev 1405 %; Δ -556.0% < -1%) |
| CFO/TA -0.44 > 3% & CFO -410.6m > Net Income -445.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (110.2m) vs 12m ago 9.09% < -2% |
| Gross Margin: -41.70% > 18% (prev 0.76%; Δ -4246 % > 0.5%) |
| Asset Turnover: 5.48% > 50% (prev 3.67%; Δ 1.81% > 0%) |
| Interest Coverage Ratio: -20.58 > 6 (EBITDA TTM -456.1m / Interest Expense TTM -22.8m) |
Altman Z'' -15.00
| A: 0.53 (Total Current Assets 581.9m - Total Current Liabilities 93.7m) / Total Assets 925.3m |
| B: -2.70 (Retained Earnings -2.49b / Total Assets 925.3m) |
| C: -0.45 (EBIT TTM -468.6m / Avg Total Assets 1.05b) |
| D: -14.10 (Book Value of Equity -2.49b / Total Liabilities 176.9m) |
| Altman-Z'' Score: -23.13 = D |
Beneish M -3.01
| DSRI: 0.93 (Receivables 11.1m/8.85m, Revenue 57.5m/43.1m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.78 (AQ_t 0.22 / AQ_t-1 0.28) |
| SGI: 1.34 (Revenue 57.5m / 43.1m) |
| TATA: -0.04 (NI -445.8m - CFO -410.6m) / TA 925.3m) |
| Beneish M-Score: -3.01 (Cap -4..+1) = AA |
What is the price of NTLA shares?
As of February 07, 2026, the stock is trading at USD 12.28 with a total of 4,610,471 shares traded.
Over the past week, the price has changed by -6.62%, over one month by +26.21%, over three months by -0.32% and over the past year by +21.22%.
Over the past week, the price has changed by -6.62%, over one month by +26.21%, over three months by -0.32% and over the past year by +21.22%.
Is NTLA a buy, sell or hold?
Intellia Therapeutics has received a consensus analysts rating of 4.34.
Therefore, it is recommended to buy NTLA.
- StrongBuy: 18
- Buy: 4
- Hold: 6
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the NTLA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 23.9 | 94.3% |
| Analysts Target Price | 23.9 | 94.3% |
| ValueRay Target Price | 9.5 | -23% |
NTLA Fundamental Data Overview February 04, 2026
P/S = 26.2957
P/B = 2.1512
P/EG = -0.0969
Revenue TTM = 57.5m USD
EBIT TTM = -468.6m USD
EBITDA TTM = -456.1m USD
Long Term Debt = 98.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 27.4m USD (from shortTermDebt, last quarter)
Debt = 98.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -95.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.10b USD (1.51b + Debt 98.0m - CCE 511.0m)
Interest Coverage Ratio = -20.58 (Ebit TTM -468.6m / Interest Expense TTM -22.8m)
EV/FCF = -2.67x (Enterprise Value 1.10b / FCF TTM -412.6m)
FCF Yield = -37.52% (FCF TTM -412.6m / Enterprise Value 1.10b)
FCF Margin = -717.3% (FCF TTM -412.6m / Revenue TTM 57.5m)
Net Margin = -774.9% (Net Income TTM -445.8m / Revenue TTM 57.5m)
Gross Margin = -41.70% ((Revenue TTM 57.5m - Cost of Revenue TTM 81.5m) / Revenue TTM)
Gross Margin QoQ = none% (prev 100.0%)
Tobins Q-Ratio = 1.19 (Enterprise Value 1.10b / Total Assets 925.3m)
Interest Expense / Debt = 9.02% (Interest Expense 8.83m / Debt 98.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -370.2m (EBIT -468.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.21 (Total Current Assets 581.9m / Total Current Liabilities 93.7m)
Debt / Equity = 0.13 (Debt 98.0m / totalStockholderEquity, last quarter 748.4m)
Debt / EBITDA = 0.21 (negative EBITDA) (Net Debt -95.4m / EBITDA -456.1m)
Debt / FCF = 0.23 (negative FCF - burning cash) (Net Debt -95.4m / FCF TTM -412.6m)
Total Stockholder Equity = 778.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.49% (Net Income -445.8m / Total Assets 925.3m)
RoE = -57.24% (Net Income TTM -445.8m / Total Stockholder Equity 778.9m)
RoCE = -53.44% (EBIT -468.6m / Capital Employed (Equity 778.9m + L.T.Debt 98.0m))
RoIC = -47.53% (negative operating profit) (NOPAT -370.2m / Invested Capital 778.9m)
WACC = 11.18% (E(1.51b)/V(1.61b) * Re(11.44%) + D(98.0m)/V(1.61b) * Rd(9.02%) * (1-Tc(0.21)))
Discount Rate = 11.44% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.37%
Fair Price DCF = unknown (Cash Flow -412.6m)
EPS Correlation: 68.08 | EPS CAGR: 108.3% | SUE: 4.0 | # QB: 1
Revenue Correlation: -1.37 | Revenue CAGR: 1.88% | SUE: -0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.99 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=8
EPS next Year (2026-12-31): EPS=-3.60 | Chg30d=-0.017 | Revisions Net=+1 | Growth EPS=+9.9% | Growth Revenue=-10.0%
P/B = 2.1512
P/EG = -0.0969
Revenue TTM = 57.5m USD
EBIT TTM = -468.6m USD
EBITDA TTM = -456.1m USD
Long Term Debt = 98.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 27.4m USD (from shortTermDebt, last quarter)
Debt = 98.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -95.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.10b USD (1.51b + Debt 98.0m - CCE 511.0m)
Interest Coverage Ratio = -20.58 (Ebit TTM -468.6m / Interest Expense TTM -22.8m)
EV/FCF = -2.67x (Enterprise Value 1.10b / FCF TTM -412.6m)
FCF Yield = -37.52% (FCF TTM -412.6m / Enterprise Value 1.10b)
FCF Margin = -717.3% (FCF TTM -412.6m / Revenue TTM 57.5m)
Net Margin = -774.9% (Net Income TTM -445.8m / Revenue TTM 57.5m)
Gross Margin = -41.70% ((Revenue TTM 57.5m - Cost of Revenue TTM 81.5m) / Revenue TTM)
Gross Margin QoQ = none% (prev 100.0%)
Tobins Q-Ratio = 1.19 (Enterprise Value 1.10b / Total Assets 925.3m)
Interest Expense / Debt = 9.02% (Interest Expense 8.83m / Debt 98.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -370.2m (EBIT -468.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.21 (Total Current Assets 581.9m / Total Current Liabilities 93.7m)
Debt / Equity = 0.13 (Debt 98.0m / totalStockholderEquity, last quarter 748.4m)
Debt / EBITDA = 0.21 (negative EBITDA) (Net Debt -95.4m / EBITDA -456.1m)
Debt / FCF = 0.23 (negative FCF - burning cash) (Net Debt -95.4m / FCF TTM -412.6m)
Total Stockholder Equity = 778.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.49% (Net Income -445.8m / Total Assets 925.3m)
RoE = -57.24% (Net Income TTM -445.8m / Total Stockholder Equity 778.9m)
RoCE = -53.44% (EBIT -468.6m / Capital Employed (Equity 778.9m + L.T.Debt 98.0m))
RoIC = -47.53% (negative operating profit) (NOPAT -370.2m / Invested Capital 778.9m)
WACC = 11.18% (E(1.51b)/V(1.61b) * Re(11.44%) + D(98.0m)/V(1.61b) * Rd(9.02%) * (1-Tc(0.21)))
Discount Rate = 11.44% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.37%
Fair Price DCF = unknown (Cash Flow -412.6m)
EPS Correlation: 68.08 | EPS CAGR: 108.3% | SUE: 4.0 | # QB: 1
Revenue Correlation: -1.37 | Revenue CAGR: 1.88% | SUE: -0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.99 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=8
EPS next Year (2026-12-31): EPS=-3.60 | Chg30d=-0.017 | Revisions Net=+1 | Growth EPS=+9.9% | Growth Revenue=-10.0%